Skip to main content
Signal8
Launch Terminal

ACHIEVE LIFE SCIENCES, INC. (ACHV)

Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.

Sector: In Vitro & In Vivo Diagnostic Substances

Industry: Biotechnology

Achieve Life Sciences, Inc. logo

Achieve Life Sciences, Inc.

NASDAQ:ACHVHealthcare
-5.01%$6.83
AH$6.79-0.59%vs close
Mkt Cap$704.19M
Float63.36M
O/S103.1M
Vol
$ Vol
RVOL
Inst Own79.6%
SI28.1%
Earnings
Dilution
Achieve Life Sciences, Inc. logoNASDAQ:ACHV$6.83-5.01%
Phase Distribution
31 lead-sponsored trials·0 active·27 completed
Phase 110
Phase 1/22
Phase 210
Phase 39
(6 more as collaborator)
Status Overview
Not yet recruiting1
Completed27
Stopped3

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Terminated

    Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer

    Taxol, TOCOSOL Paclitaxel

    Breast Neoplasm

    Enrollment
    821
    Start
    Sep 2005
    Primary Completion
    Sep 2007
    Completion
    Sep 2007
    NCT00251095
  • Phase 3
    Terminated

    A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

    custirsen sodium, isotonic, 0.9% sodium chloride

    Castrate-Resistant Prostate Cancer, Hormone Refractory Prostate Cancer

    Enrollment
    14
    Start
    Mar 2010
    Primary Completion
    Mar 2013
    Completion
    Mar 2013
    NCT01083615
  • Phase 3
    Completed

    Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer

    Custirsen, Docetaxel

    Prostate Cancer

    Enrollment
    1,022
    Start
    Nov 2010
    Primary Completion
    Feb 2014
    Completion
    Jun 2014
    NCT01188187
  • Phase 3
    Completed

    Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

    cabazitaxel, prednisone

    Prostate Cancer

    Enrollment
    630
    Start
    Aug 2012
    Primary Completion
    Jul 2016
    Completion
    Jul 2016
    NCT01578655
  • Phase 3
    Completed

    A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

    Custirsen, Docetaxel

    Non-Small Cell Lung Cancer

    Enrollment
    664
    Start
    Oct 2012
    Primary Completion
    Nov 2016
    Completion
    Nov 2016
    NCT01630733
  • Phase 3
    Completed

    A Study of Cytisinicline for Smoking Cessation in Adult Smokers

    Cytisinicline, Placebo

    Smoking Cessation

    Enrollment
    810
    Start
    Oct 2020
    Primary Completion
    Dec 2021
    Completion
    Dec 2021
    NCT04576949
  • Phase 3
    Completed

    A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers

    Cytisinicline, Placebo

    Smoking Cessation

    Enrollment
    792
    Start
    Jan 2022
    Primary Completion
    Mar 2023
    Completion
    Mar 2023
    NCT05206370
  • Phase 3
    Completed

    Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers

    Cytisinicline

    Smoking Cessation, Vaping Cessation

    Enrollment
    479
    Start
    May 2024
    Primary Completion
    Sep 2025
    Completion
    Oct 2025
    NCT06435221
  • Phase 3
    Not yet recruiting

    Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes

    Cytisinicline, Placebo

    Vaping Cessation

    Enrollment
    800
    Start
    May 2026est.
    Primary Completion
    Nov 2026est.
    Completion
    Sep 2027est.
    NCT07392125
  • Phase 2
    Completed

    Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer

    S-8184 Paclitaxel Injectable Emulsion

    Ovarian Cancer

    Enrollment
    52
    Start
    Mar 2002
    Primary Completion
    Sep 2007
    Completion
    Sep 2007
    NCT00034151
  • Phase 2
    Completed

    Safety and Efficacy of S-8184 in Second Line Treatment of Relapsed Stage IIIB or IV Non Small Cell Lung Cancer

    S-8184 Paclitaxel Injectable Emulsion

    Carcinoma, Non-Small-Cell Lung

    Enrollment
    52
    Start
    Apr 2002
    Primary Completion
    Sep 2007
    Completion
    Sep 2007
    NCT00034164
  • Phase 2
    Completed

    Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the Urothelium

    S-8184 Paclitaxel Injectable Emulsion, Experimental Arm: TOCOSOL Paclitaxel

    Urologic Neoplasms

    Enrollment
    27
    Start
    Apr 2002
    Primary Completion
    Sep 2007
    Completion
    Sep 2007
    NCT00034177
  • Phase 2
    Completed

    Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma

    S-8184 Paclitaxel Injectable Emulsion

    Colorectal Adenocarcinoma

    Enrollment
    28
    Start
    Mar 2002
    Primary Completion
    Sep 2007
    Completion
    Sep 2007
    NCT00034190
  • Phase 2
    Completed

    TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium

    TOCOSOL Paclitaxel

    Bladder Neoplasms, Ureteral Neoplasms +2

    Enrollment
    44
    Start
    Nov 2003
    Primary Completion
    -
    Completion
    Sep 2007
    NCT00077688
  • Phase 2
    Completed

    Evaluation of Safety and Efficacy of TOCOSOL(R) Paclitaxel as Initial Treatment for Metastatic Breast Cancer

    TOCOSOL(R) Paclitaxel

    Breast Cancer

    Enrollment
    47
    Start
    Oct 2004
    Primary Completion
    Sep 2007
    Completion
    Sep 2007
    NCT00096668
  • Phase 2
    Completed

    Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC

    custirsen (OGX-011)/mitoxantrone, custirsen (OGX-011)/docetaxel

    Prostate Cancer

    Enrollment
    70
    Start
    Jul 2006
    Primary Completion
    Oct 2010
    Completion
    Oct 2010
    NCT00327340
  • Phase 2
    Completed

    A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

    OGX-427 600 mg, OGX-427 1000 mg

    Urologic Neoplasms, Metastatic Bladder Cancer +1

    Enrollment
    183
    Start
    Oct 2011
    Primary Completion
    Nov 2014
    Completion
    Nov 2014
    NCT01454089
  • Phase 2
    Completed

    Trial of Cytisine in Adult Smokers

    Cytisine, Placebo Comparator

    Smoking Cessation

    Enrollment
    254
    Start
    Nov 2018
    Primary Completion
    Apr 2019
    Completion
    Apr 2019
    NCT03709823
  • Phase 2
    Completed

    A Study of Cytisinicline for Vaping Cessation in Adult Smokers

    cytisinicline, Placebo

    Vaping, E-Cig Use

    Enrollment
    160
    Start
    Jul 2022
    Primary Completion
    Feb 2023
    Completion
    Feb 2023
    NCT05431387
  • Phase 1/2
    Completed

    A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

    custirsen sodium

    Non-small Cell Lung Cancer

    Enrollment
    85
    Start
    Nov 2004
    Primary Completion
    Mar 2010
    Completion
    Mar 2010
    NCT00138658
  • Phase 1/2
    Terminated

    A Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers

    Cytisine

    Smoking Cessation

    Enrollment
    26
    Start
    Oct 2017
    Primary Completion
    Oct 2018
    Completion
    Oct 2018
    NCT03303911
  • Phase 1
    Completed

    Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors

    SN2310 Injectable Emulsion

    Breast Neoplasms, Colorectal Neoplasms +3

    Enrollment
    61
    Start
    Sep 2006
    Primary Completion
    Dec 2008
    Completion
    May 2009
    NCT00385177
  • Phase 1
    Completed

    Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer

    OGX-427, Docetaxel

    Neoplasms

    Enrollment
    64
    Start
    Jun 2007
    Primary Completion
    Jun 2011
    Completion
    Oct 2011
    NCT00487786
  • Phase 1
    Completed

    A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen

    Custirsen, paclitaxel and carboplatin

    Cancer

    Enrollment
    36
    Start
    Apr 2012
    Primary Completion
    Jul 2013
    Completion
    Oct 2013
    NCT01497470
  • Phase 1
    Completed

    Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization

    Custirsen, Placebo

    Cardiac Conduction and Repolarization

    Enrollment
    155
    Start
    May 2013
    Primary Completion
    Dec 2013
    Completion
    Jan 2014
    NCT01874561

1-25 of 31

Search ClinicalTrials.gov for “Achieve Life Sciences”